NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

May 3, 2023

Study Completion Date

August 28, 2024

Conditions

Myelofibrosis

Interventions

DRUG

Ruxolitinib

5 mg tablets for oral use

DRUG

Siremadlin

10 mg, 20 mg, or 40 mg capsules for oral use

DRUG

Crizanlizumab

100 mg/10 mL concentrate for infusion for intravenous use

DRUG

Sabatolimab

100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use

DRUG

Rineterkib

100 mg capsule for oral use

DRUG

NIS793

700 mg/7 mL concentrate for infusion for intravenous use

Trial Locations (22)

3000

Novartis Investigative Site, Melbourne

3004

Novartis Investigative Site, Melbourne

5000

Novartis Investigative Site, Adelaide

8091

Novartis Investigative Site, Zurich

9007

Novartis Investigative Site, Sankt Gallen

14186

Novartis Investigative Site, Stockholm

17475

Novartis Investigative Site, Greifswald

28034

Novartis Investigative Site, Madrid

35010

Novartis Investigative Site, Las Palmas de Gran Canaria

37007

Novartis Investigative Site, Salamanca

41380

Novartis Investigative Site, Kocaeli

50134

Novartis Investigative Site, Florence

68305

Novartis Investigative Site, Mannheim

79106

Novartis Investigative Site, Freiburg im Breisgau

125284

Novartis Investigative Site, Moscow

M5G 2M9

Novartis Investigative Site, Toronto

DK-2100

Novartis Investigative Site, Copenhagen

07740

Novartis Investigative Site, Jena

H-1083

Novartis Investigative Site, Budapest

1081 HV

Novartis Investigative Site, Amsterdam

03010

Novartis Investigative Site, Alicante

SE1 9RT

Novartis Investigative Site, London